Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis

Rosenberg, Tine; Philipsen, Bahareh Bakhshaie; Mehlum, Camilla Slot; Dyrvig, Anne-Kirstine; Wehberg, Sonja; Chirilă, Magdalena; Godballe, Christian

doi:10.1093/infdis/jiy616

Cited by 64 publications

(55 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, available HPV vaccines are safe and tolerable [18–20] and a persistent cross-reactive immune response against HR-HPV not covered by the vaccine was shown in vaccinated women [21]. However, vaccination has a clinically relevant role also in subjects with established HPV infection [13, 22]. We analysed the HR-HPV patterns in HIV-positive MSM retained in care in a tertiary level hospital of a high-income country that provides free care and therapy, which is the best clinical scenario.…”

Section: Discussionmentioning

confidence: 99%

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications

et al. 2019

View full text Add to dashboard Cite

Background Few studies focused on longitudinal modifications over time of high-risk HPV (HR-HPV) at anal and oral sites in HIV+ men who have sex with men (MSM). Methods We described patterns and longitudinal changes of HR-HPV detection and the prevalence of HR-HPV covered by the nonavalent HPV vaccine (vax-HPV) at oral and anal sites in 165 HIV+ MSM followed in an Italian hospital. The samples were collected at baseline and after 24 months (follow-up). The presence of HPV was investigated with Inno-LiPA HPV Genotyping Extra II. Results Median age was 44 years (IQR 36–53), median CD4+ cell count at nadir was 312 cells/mm 3 (IQR 187–450). A total of 120 subjects (72.7%) were receiving successful antiretroviral therapy (ART). At baseline and follow-up, the frequency of HR-HPV was significantly higher in the anal site (65.4% vs 9.4 and 62.4% vs 6.8%, respectively). Only 2.9% of subjects were persistently HR-HPV negative at both sites. All oral HR-HPV were single at baseline vs 54.6% at baseline at the anal site ( p = 0.005), and all oral HR-HPV were single at follow-up vs 54.4% at anal site at follow-up ( p = 0.002). The lowest rate of concordance between the oral and anal results was found for HR-HPV detection; almost all HR-HPV positive results at both anal and oral sites had different HR-HPV.The most frequent HR-HPV in anal swabs at baseline and follow-up were HPV-16 and HPV-52.At follow-up at anal site, 37.5% of patients had different HR-HPV genotypes respect to baseline, 28.8% of subjects with 1 HR-HPV at baseline had an increased number of HR-HPV, and patients on ART showed a lower frequency of confirmed anal HR-HPV detection than untreated patients ( p = 0.03) over time. Additionally,54.6 and 50.5% of patients had only HR-vax-HPV at anal site at baseline and follow-up, respectively; 15.2% had only HR-vax-HPV at baseline and follow-up. Conclusions We believe that it is important testing multiple sites over time in HIV-positive MSM. ART seems to protect men from anal HR-HPV confirmed detection. Vaccination programmes could reduce the number of HR-HPV genotypes at anal site and the risk of the first HR-HPV acquisition at the oral site. Electronic supplementary material The online version of this article (10.1186/s12889-019-7004-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A systematic review and meta-analysis found a statistically significant reduction in the mean number of surgical procedures per month after HPV vaccination. 91 The proposed mechanisms of action include inhibition of latent HPV infection in the mucosa surrounding the surgical site by the antibody-mediated humoral immune response to the vaccine and activation of the cell-mediated response in the adaptive immune response by vaccination.…”

Section: Disease Coursementioning

confidence: 99%

<p>Juvenile-Onset Recurrent Respiratory Papillomatosis Diagnosis and Management – A Developing Country Review</p>

Seedat

2020

PHMT

View full text Add to dashboard Cite

Recurrent respiratory papillomatosis (RRP) is a condition caused by human papillomavirus (HPV), usually HPV types 6 and 11, which is characterized by recurrent papillomas of the respiratory tract, mainly the larynx. Patients usually present between the ages of 2 and 6 years. The initial presenting symptom is progressive dysphonia, followed by stridor and respiratory distress. Treatment consists of repeated microlaryngoscopic procedures to remove the papillomas as there is no cure. The poor availability and accessibility of appropriate healthcare services in developing countries are barriers to the early diagnosis and appropriate management of patients with juvenile-onset recurrent respiratory papillomatosis (JoRRP), requiring many patients to have a tracheostomy. The introduction of prophylactic vaccines that include HPV6 and HPV11 is necessary in order to reduce the incidence of JoRRP.

show abstract

“…The tetravalent vaccine acts targets HPV-6, HPV-11, HPV-16, HPV-18. A recent systematic review and meta-analysis found that the mean duration between surgeries in 63 juvenile and adult RRP patients significantly increased after HPV vaccination, from 7 to 34 months on average (25). The study found no significant differences by age of RRP onset (25).…”

Section: Hpv Vaccinementioning

confidence: 99%

Airway Papillomatosis: New Treatments for an Old Challenge

Kumar

Preciado

2019

Front. Pediatr.

View full text Add to dashboard Cite

Recurrent respiratory papillomatosis (RRP) is the recurrent growth of small, benign tumors, or papillomas, in the respiratory tract, caused by human papillomavirus (HPV). Currently, there is no cure. Palliative treatments seek to prevent airway obstruction, keep underlying tissues healthy, and maintain voice quality. The most common intervention, the local surgical removal of papillomas, may be inadequate as a standalone treatment for pediatric populations that experience rapid papilloma regrowth, as repeated surgeries cause increased damage to the surrounding tissues and impose significant emotional and economic burden on families. Interferon α and Cidofovir have been shown to lengthen the time between surgical interventions and/or decrease the total number of procedures needed, although the evidence of their efficacy and safety is controversial. Novel therapies, including photodynamic therapy, indole-3-carbinol, anti-reflux medication, heat shock protein, and Mumps and HPV vaccination, may provide potential avenues for treatment, but require further research. Among all the novel therapies investigated, systemic bevacizumab seems to offer the most promising alternative to surgery. Randomized control trials to investigate its impact, especially in a pediatric population, should be conducted before implementing it as a standard form of care. This review will summarize the latest literature on medical care for aggressive RRP disease.

show abstract

Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis

Abstract: This updated and thorough review and meta-analyses supports the continued use of the HPV vaccine as an adjuvant treatment of RRP as significantly fewer surgeries per month are required after vaccination.

Cited by 64 publications

References 49 publications

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications

<p>Juvenile-Onset Recurrent Respiratory Papillomatosis Diagnosis and Management – A Developing Country Review</p>

Airway Papillomatosis: New Treatments for an Old Challenge

Contact Info

Product

Resources

About